ATE444072T1 - Prävention von epithelzellkarzinom - Google Patents

Prävention von epithelzellkarzinom

Info

Publication number: ATE444072T1
Authority: AT; Austria
Prior art keywords: cancer; prevention; prostate; bladder; lung
Prior art date: 2001-04-05

Application number

AT02759763T

Other languages

English (en)

Inventor

Hans Raskov

Original Assignee

Colotech As

Raskov Hans Henrik

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-05

Filing date

2002-04-05

Publication date

2009-10-15

2001-04-05 Priority claimed from US09/825,891 external-priority patent/US6703380B2/en

2002-04-05 Application filed by Colotech As, Raskov Hans Henrik filed Critical Colotech As

2009-10-15 Application granted granted Critical

2009-10-15 Publication of ATE444072T1 publication Critical patent/ATE444072T1/de

Links

201000009030 Carcinoma Diseases 0.000 title abstract 6
230000002265 prevention Effects 0.000 title abstract 3
210000002919 epithelial cell Anatomy 0.000 title 1
206010028980 Neoplasm Diseases 0.000 abstract 4
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 abstract 4
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 abstract 4
201000011510 cancer Diseases 0.000 abstract 4
210000004072 lung Anatomy 0.000 abstract 4
210000002307 prostate Anatomy 0.000 abstract 4
210000003932 urinary bladder Anatomy 0.000 abstract 4
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 3
239000011575 calcium Substances 0.000 abstract 3
239000002207 metabolite Substances 0.000 abstract 3
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 abstract 3
235000005282 vitamin D3 Nutrition 0.000 abstract 3
239000011647 vitamin D3 Substances 0.000 abstract 3
229940021056 vitamin d3 Drugs 0.000 abstract 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 2
229910052791 calcium Inorganic materials 0.000 abstract 2
239000003112 inhibitor Substances 0.000 abstract 2
230000000977 initiatory effect Effects 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
230000002113 chemopreventative effect Effects 0.000 abstract 1
238000011260 co-administration Methods 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
231100000252 nontoxic Toxicity 0.000 abstract 1
230000003000 nontoxic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)

AT02759763T 2001-04-05 2002-04-05 Prävention von epithelzellkarzinom ATE444072T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/825,891 US6703380B2 (en)	1999-09-29	2001-04-05	Prevention of cancer
PCT/DK2002/000231 WO2002080889A2 (en)	2001-04-05	2002-04-05	A combination dosage of a cyclooxygenase (cox) inhibitor, a vitamin d3 including analogues and metabolites thereof and/or calcium for prevention of epithelial cancer

Publications (1)

Publication Number	Publication Date
ATE444072T1 true ATE444072T1 (de)	2009-10-15

Family

ID=25245159

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02759763T ATE444072T1 (de)	2001-04-05	2002-04-05	Prävention von epithelzellkarzinom

Country Status (12)

Country	Link
EP (1)	EP1389122B1 (de)
AT (1)	ATE444072T1 (de)
AU (1)	AU2002338311B2 (de)
CA (1)	CA2445940C (de)
DE (1)	DE60233869D1 (de)
DK (1)	DK1389122T3 (de)
ES (1)	ES2334215T3 (de)
IS (1)	IS6976A (de)
NO (1)	NO20034381L (de)
NZ (1)	NZ529104A (de)
PT (1)	PT1389122E (de)
WO (1)	WO2002080889A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI20135701L (fi) *	2013-06-26	2014-12-27	Mas Metabolic Analytical Services Oy	Farmaseuttisesti käyttökelpoinen ja turvallinen kombinaatio käytettäväksi merkittävien sairauksien hoidossa

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5948443A (en) *	1996-02-23	1999-09-07	Medical Doctor's Research Institute, Inc.	Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease
CA2385755C (en) *	1999-09-29	2007-02-06	Colotech A/S	Prevention of colorectal cancer

2002
- 2002-04-05 PT PT02759763T patent/PT1389122E/pt unknown
- 2002-04-05 CA CA2445940A patent/CA2445940C/en not_active Expired - Fee Related
- 2002-04-05 AU AU2002338311A patent/AU2002338311B2/en not_active Ceased
- 2002-04-05 WO PCT/DK2002/000231 patent/WO2002080889A2/en not_active Ceased
- 2002-04-05 DK DK02759763.2T patent/DK1389122T3/da active
- 2002-04-05 DE DE60233869T patent/DE60233869D1/de not_active Expired - Lifetime
- 2002-04-05 ES ES02759763T patent/ES2334215T3/es not_active Expired - Lifetime
- 2002-04-05 EP EP02759763A patent/EP1389122B1/de not_active Expired - Lifetime
- 2002-04-05 NZ NZ529104A patent/NZ529104A/en unknown
- 2002-04-05 AT AT02759763T patent/ATE444072T1/de not_active IP Right Cessation
2003
- 2003-10-01 NO NO20034381A patent/NO20034381L/no not_active Application Discontinuation
- 2003-10-03 IS IS6976A patent/IS6976A/is unknown

Also Published As

Publication number	Publication date
ES2334215T3 (es)	2010-03-08
WO2002080889A2 (en)	2002-10-17
CA2445940A1 (en)	2002-10-17
NO20034381D0 (no)	2003-10-01
WO2002080889A3 (en)	2003-02-20
PT1389122E (pt)	2009-12-23
IS6976A (is)	2003-10-03
DE60233869D1 (de)	2009-11-12
EP1389122B1 (de)	2009-09-30
DK1389122T3 (da)	2010-02-01
EP1389122A2 (de)	2004-02-18
NO20034381L (no)	2003-12-05
NZ529104A (en)	2004-05-28
CA2445940C (en)	2010-08-24
AU2002338311B2 (en)	2006-08-10

Similar Documents

Publication	Publication Date	Title
BRPI0410503A (pt)	2006-06-20	uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
BRPI0207961A8 (pt)	2017-09-19	Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
EA201300242A1 (ru)	2013-11-29	Фармацевтические композиции, содержащие замещенные ациланилиды
IL175158A0 (en)	2006-09-05	Tocopherol-modified therapeutic drug compounds
NO20062504L (no)	2006-07-21	Sammensetninger og doseringsformer for forbedret absorpsjon
TW200612987A (en)	2006-05-01	Combination treatment for non-hematologic malignancies
IL154888A (en)	2013-12-31	Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
AR109263A2 (es)	2018-11-14	Composición que comprende moxidectina
DK1680128T3 (da)	2007-06-11	Myo-inositolhexaphosphat til topisk anvendelse
CL2015001086A1 (es)	2016-05-13	Combinación farmacéutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas
DE60019947D1 (de)	2005-06-09	Vorbeugung von kolorektalkrebs
CY1110369T1 (el)	2015-04-29	Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
UY26171A1 (es)	2000-12-29	Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
BRPI0415232A (pt)	2006-12-12	uso de xenÈnio com hipotermia para tratar asfixia neonatal
PL368686A1 (en)	2005-04-04	Novel aminobenzoephenones
BRPI0508333A (pt)	2007-07-17	uso de um composto de vitamina d, método de prevenir e/ou tratar cistite intersticial, formulação farmacêutica, composto de vitamina d, e, kit
TR200302134T4 (tr)	2004-01-21	2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
ATE444072T1 (de)	2009-10-15	Prävention von epithelzellkarzinom
BRPI0519006A2 (pt)	2008-12-23	uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
WO2005105135A8 (en)	2006-12-07	Il-6 for therapy or prevention of chemotherapy-induced neuropathy
SE0203817D0 (sv)	2002-12-20	New composition
ATE346080T1 (de)	2006-12-15	Steroid-verbindungen mit anti-tumoraler wirkung
IS2392B (is)	2008-08-15	Sítalópram til að meðhöndla hækkaðan blóðþrýsting
DK1962822T3 (da)	2010-05-17	Terapi af maligne neoplasier
GT200400014A (es)	2004-09-21	Metodo de tratamiento con nelfinavir

Legal Events

Date

Code

Title

Description

2010-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1389122

Country of ref document: EP

2012-01-15

REN

Ceased due to non-payment of the annual fee